Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — Shareholder Meeting (November 2021)

28 slides from Kazia Therapeutics's shareholder meeting presentation, Nov 10, 2021

  1. Slide 1: Presentation to Annual General Meeting of Shareholders

    Presentation to Annual General Meeting of Shareholders Dr James Garner Chief Executive Officer Sydney, NSW 10 November 2021 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All state

  3. Slide 3: 2021 in Review: A Year of Achievements

    2021 in Review A Year of Achievements 3 $15M 11 179% Major cross-border Ongoing clinical Total shareholder licensing deals in Revenue in FY2021 studies across two return (TSR) FY2021 clinical programs (Jul 20 to Jun 21) Phase III 3 >200 Phase I Paxalisib pivotal New paxalisib trial Patients now EVT8

  4. Slide 4: Financial Performance

    Financial Performance Building sustainable shareholder value 3

  5. Slide 5: Share price performance has begun to reflect Kazia's value proposition

    Share price performance has begun to reflect Kazia’s value proposition Kazia Share Price (AU$) 2.00 1.80 1.60 Kazia Therapeutics 1.40 ↑ 179% 1.20 1.00 NASDAQ S.C. Biotech 0.80 ↑ 31% 0.60 S&P/ASX200 0.40 ↑ 23% NASDAQ Biotech 0.20 ↑ 19% 0.00 01-Jul-20 01-Oct-20 01-Jan-21 01-Apr-21 01-Jul-21 Kazia (ASX

  6. Slide 6: Kazia's enterprise value has increased by approximately 37x in five years

    Kazia’s enterprise value has increased by approximately 37x in the last five years 200 180 $173M 160 140 120 100 80 60 $44M $37M 40 $20M $19M $20M 20 0 Jun-16 Jun-17 Jun-18 Jun-19 Jun-20 Jun-21 Enterprise Value Cash Source: Company Annual Reports; Marketwatch 5

  7. Slide 7: Financing cashflows essentially matched by non-dilutive income

    Financing cashflows have been essentially matched by non- dilutive income from other sources Inward Cashflows (AU$) FY2021 FY2020 FY2019 FY2018 Cashflows from Operations FY2017 Cashflows from Financing 0 10 20 30 40 50 60 $40 million $42 million Sustainable Growth from operations from financing Sour

  8. Slide 8: Research coverage has deepened, with five analysts now following

    Research coverage has deepened, with five analysts now following Kazia’s progress Australia United States AU$ 2.50 AU$ 2.60 AU$ 2.83 US$ 17.00 US$ 18.00 (May 2021) (Apr 2021) (Oct 2021) (Apr 2021) (Oct 2021) 7

  9. Slide 9: Paxalisib: Progressing towards commercialisation

    Paxalisib Progressing towards commercialisation 8

  10. Slide 10: Primary market research suggests strong clinician support for paxalisib

    Primary market research suggests strong clinician support for paxalisib, if successful in clinical trials Unmet Need in Glioblastoma Paxalisib Mechanism of Action No Unmet Extreme Unmet Very Negative Very Positive Need Need Impression Impression 6.7 5.1 1 2 3 4 5 6 7 1 2 3 4 5 6 7 Average Rating by

  11. Slide 11: Adoption rate expected to be very high due to scarcity of treatment options

    Adoption rate for the commercial product is expected to be very high, due to scarcity of existing treatment options Newly-Diagnosed Unmethylated Recurrent Extension of Overall Survival (months) Extension of Overall Survival (months) Optimal 7.0 mos. Optimal 4.8 mos. Minimum 2.6 mos. Minimum 2.1 mos.

  12. Slide 12: Pricing comparators indicate monthly cost around US$12K in United States

    Pricing comparators indicate monthly treatment costs for paxalisib around US$ 12K in United States Median Annual Cost of Current or Forecast Monthly Pricing of Select Comparator New Oncology Products Products (United States) at Launch (United States) Annual Cost (US$) Monthly Cost (US$ ,000) 180,000

  13. Slide 13: Payer interviews support willingness-to-pay up to US$20K in US

    Payer interviews support willingness-to-pay up to US$ 20K in US and up to ~$10K in EU5 United States European Union Likelihood of Coverage for Paxalisib Likelihood of Coverage for Paxalisib Very 7 Very 7 Favourable Favourable 6 6 5 5 4 4 3 3 2 2 1 1 Not At All Not At All Favourable Favourable 0 0 $8

  14. Slide 14: Paxalisib: A strong competitive position

    Paxalisib A strong competitive position 13

  15. Slide 15: Paxalisib could be ready for commercial launch in CY2024

    INDICATIVE Paxalisib could be ready for commercial launch in CY2024 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 GLP Toxicology Technical Development Phase II Study ADME Study Pivotal Study Commercial Manufacture United States Europe China Note: Actual timelines will depend on clinical trial pe

  16. Slide 16: Glioblastoma is a less competitive indication

    Glioblastoma is a less competitive indication, in terms of number of approved products and number of ongoing trials 0 Number of Testicular Lower Competitive Intensity Thyroid Esophageal Phase II and III Clinical 100 Renal Gastric Trials 200 Cervix 100,000 cases Colorectal Pancreatic Uterine per annu

  17. Slide 17: Late-stage pipeline remains limited, with paxalisib among leading candidates

    Late-stage pipeline remains limited, with paxalisib among leading candidates for first new GBM drug since Temodar® Company Product Mechanism Phase Population Efficacy Safety Notes Paxalisib PI3K /mTOR III ND unmeth. OS: ↑4.8 mos. Rash; mucositis; inhibitor Recurrent (ND unmeth.) hyperglycemia Partic

  18. Slide 18: Launch of new pharmaceutical products typically expands the class

    Launch of new pharmaceutical products typically expands, rather than cannibalises, the class Breast Cancer US$ billion US$ billion OVERALL ↑ 40% 20 Alpelisib approved May 19 20 $17.5B Others ↓ 7% Talazoparib approved Oct 18 PI3K Inhibitors (new) 15 $12.5B 15 Olaparib approved Jan 18 PARP Inhibitors

  19. Slide 19: EVT801: Entering an exciting and rapidly-evolving new domain

    EVT801 Entering an exciting and rapidly-evolving new domain 18

  20. Slide 20: EVT801 is now a clinical-stage asset

    EVT801 is now a clinical-stage asset 19

  21. Slide 21: Targeting angiogenesis is a well-established approach in cancer treatment

    Targeting angiogenesis is a well-established approach in the treatment of cancer Product Company Target Indications Annual Sales (US$)* • Colorectal cancer VEGF-A • Lung cancer $7 billion • Breast cancer VEGFR • Hepatocellular carcinoma PDGFR • Renal call carcinoma $1 billion RAF kinases • Thyroid c

  22. Slide 22: Angiogenesis inhibitors are limited by several key challenges

    Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges 1 Angiogenesis inhibitors work by reducing Tumor Hypoxia the formation of new blood vessels around the tumor, starving it of vital Sustained tumor hypoxia activates adaptive mechanisms, Limited nutrients nee

  23. Slide 23: EVT801 is a selective VEGFR inhibitor inhibiting lymphangiogenesis

    EVT801 is a selective VEGFR inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels) Highly selective for VEGFR3 Oral Presentation Expected to minimise off-target toxicities Administered by mouth once or twice daily Inhibits lymphangiogenesis Strong IP Protection Compos

  24. Slide 24: Focus in angiokinase inhibitor class has shifted to immuno-oncology use

    Focus in the ‘angiokinase inhibitor’ class has shifted from anti-angiogenic use to immuno-oncology use Select VEGFR Inhibitors – FDA Approvals – 2012-2021 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Renal Renal Cancer Cancer (MonoTx) with Thyroid Renal Liver Endomet- Renal Cancer Cancer Cancer

  25. Slide 25: FDA approvals mirrored by increase in immunotherapy combination trial activity

    Recent FDA approvals are mirrored by a striking increase in immunotherapy combination trial activity Number of Clinical Trial Starts Number of Clinical Trial Starts Number of Clinical Trial Starts 25 25 25 20 20 20 15 15 15 10 10 10 5 5 5 0 0 0 Anti-angiogenesis Immunotherapy Anti-angiogenesis Immun

  26. Slide 26: EVT801 exhibits potent synergy with checkpoint inhibitors

    EVT801 exhibits at least as potent synergy with checkpoint inhibitors as other agents Tumor Volume (mm3) Experimental Methods 500 • Orthotopic mouse model Vehicle • 4T1 tumor cells inoculated in BALB/c EVT801 mice (mammary fat pad) 400 anti-CTLA4 • Treatment with EVT801 on D7-D21 EVT801 + anti-CTLA4

  27. Slide 27: Kazia's strategy for EVT801 explores both areas of opportunity

    PRELIMINARY Kazia’s strategy for EVT801 aims to explore both areas of opportunity for the drug Explore EVT801 as Phase II Study Pivotal Study an anti-angiogenic therapy, likely in Monotherapy Monotherapy tumours that express high One or more solid One or more solid VEGFR3 tumours tumours Phase I Stu

  28. Slide 28: www.kaziatherapeutics.com

    www.kaziatherapeutics.com info@kaziatherapeutics.com

Kazia Therapeutics — Shareholder Meeting (November 2021) on 6ix